February 7, 2023

George Vradenburg – The Future of Alzheimer’s Advocacy Part 2

George Vradenburg – The Future of Alzheimer’s Advocacy Part 2

About This Episode

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative. They explore the implications of the approval of Lecanemab (or Leqembi) worldwide and whether the approval encourages healthy at-risk adults 50 plus to understand their dementia risk profile.

BrainStorm Feed

40

Amy Dockser Marcus, Author of "We the Scientists" (part 1)

We the Scientists: How a Daring Team of Parents and Doctors Forged A New Path for Medicine

LISTEN NOW
39

Sandra Bond Chapman, PhD and the Importance of Lifelong Brain Health (part 2)

Want to improve your brain’s performance? Find out the latest from Dr.

LISTEN NOW
38

Sandra Bond Chapman Ph.D. and the Importance Lifelong Brain Health - Part 1

Want to improve your brain’s performance? Why not? You’re using it anyway. Find out the latest from Dr.

LISTEN NOW